- Home
- SUGP vs CARM Comparison
SUGP vs CARM Comparison
Compare SUGP & CARM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SUGP
- CARM
- Stock Information
- Founded
- SUGP 1998
- CARM 2016
- Country
- SUGP Hong Kong
- CARM United States
- Employees
- SUGP N/A
- CARM N/A
- Industry
- SUGP
- CARM Biotechnology: Pharmaceutical Preparations
- Sector
- SUGP
- CARM Health Care
- Exchange
- SUGP NYSE
- CARM Nasdaq
- Market Cap
- SUGP 20.3M
- CARM 17.4M
- IPO Year
- SUGP 2024
- CARM N/A
- Fundamental
- Price
- SUGP $1.17
- CARM $0.44
- Analyst Decision
- SUGP
- CARM Hold
- Analyst Count
- SUGP 0
- CARM 5
- Target Price
- SUGP N/A
- CARM $4.57
- AVG Volume (30 Days)
- SUGP 510.4K
- CARM 277.1K
- Earning Date
- SUGP 01-28-2025
- CARM 11-07-2024
- Dividend Yield
- SUGP N/A
- CARM N/A
- EPS Growth
- SUGP N/A
- CARM N/A
- EPS
- SUGP 0.10
- CARM N/A
- Revenue
- SUGP $20,252,232.00
- CARM $20,268,000.00
- Revenue This Year
- SUGP N/A
- CARM $46.34
- Revenue Next Year
- SUGP N/A
- CARM N/A
- P/E Ratio
- SUGP $11.40
- CARM N/A
- Revenue Growth
- SUGP N/A
- CARM 41.13
- 52 Week Low
- SUGP $0.76
- CARM $0.38
- 52 Week High
- SUGP $5.86
- CARM $2.77
- Technical
- Relative Strength Index (RSI)
- SUGP 46.38
- CARM 37.99
- Support Level
- SUGP $1.09
- CARM $0.42
- Resistance Level
- SUGP $1.26
- CARM $0.48
- Average True Range (ATR)
- SUGP 0.14
- CARM 0.06
- MACD
- SUGP 0.01
- CARM 0.01
- Stochastic Oscillator
- SUGP 34.15
- CARM 18.67
About SUGP SU GROUP HLDGS LTD
SU Group Holdings Ltd and its subsidiaries is an integrated security-related services company. The company has two reportable segments: security-related engineering services, and security guarding and screening services and related vocational training services. The company generates the majority of its revenue from the security-related engineering services segment.
About CARM Carisma Therapeutics Inc.
CARISMA Therapeutics Inc is a clinical-stage cell therapy company focused on utilizing Carisma's proprietary chimeric antigen receptor macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. The company has created a comprehensive cell therapy platform to enable the therapeutic use of engineered macrophages and monocytes, which belong to a subgroup of white blood cells called myeloid cells.